ABCD1 and X-linked adrenoleukodystrophy: Together with these, the capacity of SAHA to cross blood brain barrier [79], induce ABCD2 gene in brain (Fig. 10), lower VLCFA levels in Abcd1-KO brain, and good oral bioavailability and safety in long-term treatments in pediatric patients [90], provide a proof-of-principle for use of SAHA in X-ALD therapy.